Condition: Aneurysmal Subarachnoid Hemorrhage · Sponsor: University Hospital, Toulouse
The present study is a randomized, multi-center, double-blind, prospective study that tests the efficacy of intravenous milrinone to optimize cerebral hemodynamic and prevent delayed cerebral ischemia (DCI) during the high-risk period (day 4- day 14) in patients with severe subarachnoid hemorrhage due to intracranial aneurysm rupture (SAHa) (WFNS IV-V). The main objective is to evaluate, in comatose patients and / or sedated on D3 following a severe SAHa (WFNS IV -V), the effect of 10 days of milrinone versus placebo, in addition to the usual management, on the volume of DCI lesions measured on CT scan at 1 month.
This description comes directly from the study's public registry record.
Thomas Geeraerts, MD PhD · 056-177-2100 · geeraerts.t@chu-toulouse.fr
Nadera AINAOUI · 056-177-2498 · nadera.ainaoui@inserm.fr
Always discuss trial participation with your own doctor first.
| University Hospital Bordeaux | Bordeaux, France | Active Not Recruiting |
| CHUGA | Grenoble, France | Active Not Recruiting |
| University Hospital of La Réunion | La Réunion, France | Recruiting |
| HCL | Lyon, France | Recruiting |
| University Hospital of Toulouse | Toulouse, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04282629